laboratory investigation J neurosurg spine 25:154-164, 2016 abbreviations ACS = absorbable collagen sponge; ADJ = sponge placed adjacent to the nerve; BMP = bone morphogenetic protein; CCI = chronic constriction injury; H & E = hematoxylin and eosin; rhBMP-2 = recombinant human BMP-2; WRP = sponge wrapped around the nerve. obJeCtive It has been hypothesized that the recombinant human bone morphogenetic protein-2 (rhBMP-2) amplification of the host inflammatory response interacts with nerves in the spine and contributes to the occurrence of new, postoperative complaints of radiculitis. This in vivo rat study was conducted to assess the capacity for rhBMP-2/ACS (rhBMP-2 applied to absorbable collagen sponge [ACS]) to stimulate pain-associated behaviors in the rat chronic constriction injury (CCI) model. MethoDs Rats were randomly assigned to one of 14 treatment groups. Half of the animals underwent a sham procedure in which the left sciatic nerve was exposed and manipulated but no ligature was placed (Sham cohort), while the remaining animals had chromic gut sutures tied around the sciatic nerve to induce CCI (CCI cohort). The following test articles were applied to the sciatic nerve in each cohort: saline alone, saline applied to ACS, 0.1 mg/ml rhBMP-2 applied to ACS, or 1.0 mg/ml rhBMP-2 applied to ACS. The ACS was either wrapped around the sciatic nerve or implanted adjacent to the nerve. Thermal withdrawal latency was assessed on Days 7, 14, 21, and 28 postoperatively. Isolated nerves from selected rats in each group were examined and assessed for histopathological changes on Days 3, 7, 14, and 28. resUlts CCI produced a significant pain behavioral response for all treatment groups at all time points. In the Sham cohort, 0.1 mg/ml rhBMP-2/ACS wrapped around the nerve (WRP) decreased thermal withdrawal on Day 28, and 1.0 mg/ml rhBMP-2/ACS placed adjacent to the nerve (ADJ) decreased thermal withdrawal on Days 21 and 28. Conversely, in the CCI cohort, 0.1 mg/ml rhBMP-2/ACS ADJ increased thermal withdrawal latencies on Day 7; 1.0 mg/ml rhBMP-2/ ACS ADJ increased thermal withdrawal latencies on Day 7; and 1.0 mg/ml rhBMP-2/ACS WRP increased thermal withdrawal on Days 7 and 14. Histologically, the effect of rhBMP-2 on nerve inflammation was unclear, as inflammatory cell infiltration was similar in the rhBMP-2/ACS and saline/ACS groups. rhBMP-2 was variably associated with bone formation within the epineurium at 14 days, and more prevalently at 28 days, with no clear relationship between dose or ACS positioning. ConClUsions In this study, rhBMP-2/ACS did not appear to induce pain independent of grossly visible ectopic bone formation. At the earliest time points, rhBMP-2 appeared to have a neuroprotective effect as evidenced by decreased pain exhibited by the rhBMP-2-treated animals in the CCI cohort, but this effect diminished over time, and by Day 28, the pain behavioral responses in the rhBMP-2-treated group were comparable to those in the group in which saline was applied to the nerve. In the Sham cohort, there was a dose-independent induction of pain at later time points, presumably due to new bone formation mechanically irritating the nerve. Histological examination revealed nerve lesions that appeared to be caused by mechanical trauma associated with surgical manipulation of the nerve during placement of the ACS and/or CCI sutures.
B
one morphogenetic proteins (BMPs) are multifunctional growth and differentiation factors that were originally identified for their ability to induce endochondral bone formation.
14, 25 The most extensively studied member of this family is BMP-2. This protein facilitates bone repair, a process that involves the complex coordination of resorbing damaged bone with the formation of new bone matrix at fracture sites. The most frequently used clinically available product containing recombinant human BMP-2 (rhBMP-2), INFUSE Bone Graft (Medtronic plc), is approved by the US Food and Drug Administration as an osteoinductive bone graft for use in specific indications.
Local surgical implantation of supraphysiological doses of rhBMP-2 are required to achieve bone fusion. 1 The implantation of these higher protein doses has raised concerns regarding the in vivo amplification of the host inflammatory response 11, 19 that is integral to bone healing.
21 Such concerns appear to be supported by the work of Salisbury et al. 23 that suggests that BMP-2 acts on peripheral nerves in a process that includes the direct induction of neuroinflammation. It has been theorized that new complaints of postoperative radiculitis following spine fusion procedures using INFUSE bone graft may be related to a direct action of rhBMP-2 on spinal nerves within the surgical field.
11
In this study, rhBMP-2 applied to absorbable collagen sponge (ACS) was evaluated for the potential to affect pain-associated behaviors following implantation directly adjacent to or wrapped around the sciatic nerve in the rat chronic constriction injury (CCI) model. This well-validated animal model 16 was chosen because it involves a mechanical injury to the sciatic nerve and an inflammatory pain response that is reliable and easily reproducible.
2, 3 The animals were assigned to one of 2 cohorts. Animals in the CCI cohort were subjected to surgical placement of inflammation-inducing sutures to assess whether rhBMP-2/ACS could amplify the pain behavioral responses achieved with this model. Animals in the other cohort (the Sham cohort) were subjected to surgical manipulation of the sciatic nerve without placement of the ligatures to assess whether the rhBMP-2/ACS alone could elicit a pain response.
Methods graft Preparation
Saline (1× phosphate buffered saline) was purchased from Sigma-Aldrich Co. LLC. Medtronic plc provided the 0.1 mg/ml and 1.0 mg/ml rhBMP-2 solutions. The rhBMP-2 carrier used in this study was an absorbable bovine collagen sponge (ACS, Integra LifeSciences Corp.) cut into 1.0 cm × 0.8 cm × 0.35 cm strips (0.28 cm 3 per sponge). The ACS was hydrated with 0.3 ml of saline or rhBMP-2 solution, and allowed to soak for a minimum of 15 minutes and a maximum of 90 minutes before implantation.
surgical Procedures
Two hundred thirty-eight male Sprague-Dawley rats (Harlan Laboratories) were used in this study. The animals' mean weight (± SD) on the day of surgery (Day 0) was 323.3 ± 29.6 g. All experiments were conducted in accordance with the International Association for the Study of Pain guidelines and approved by the Institutional Animal Care and Use Committee at SRI International, Inc. Each animal was anesthetized by intraperitoneal injection of sodium pentobarbital at a dose of 60 mg/kg, and anesthesia was maintained with continuous isoflurane inhalation (adjusted from 1% to 3% as needed). The animal's left sciatic nerve was exposed and freed from adherent tissue at midthigh using a lateral approach, separating the biceps femoris and quadriceps muscles by blunt dissection. Seventeen animals were randomly assigned to each treatment group (Table 1 ). In half of the animals (Groups 8-14), CCI was induced according to the method of Bennett and Xie, 3 where 4 loose chromic gut sutures (4-0 absorbable suture, Jorgensen Laboratories, Inc.) were placed 1 mm apart around the nerve. In the animals in the Sham cohort (Groups 1-7), the sciatic nerve was lifted from the muscle pocket and exposed in a manner simulating the application of the ligatures, but no ligatures were placed.
Animals receiving saline only had the liquid applied with a syringe directly on the sciatic nerve. Animals that received the ACS had it wrapped around the sciatic nerve at midthigh (WRP) or implanted adjacent to the nerve (ADJ). In the WRP groups, the ACS was applied by passing it beneath the sciatic nerve without stretching the nerve and wrapping it loosely around the nerve to minimize constriction. In the ADJ groups, the ACS was rolled and placed next to and in contact with the nerve.
assessment of behavior
Pain behavioral response was evaluated in 8 animals per group by measurement of withdrawal latency following exposure to a noxious thermal stimulus according to the Hargreaves test. 8 The same 8 animals were tested at each time point. Measurements were taken 2 days prior to surgery to establish a baseline response for each animal, then repeated at Days 7, 14, 21, and 28 postoperatively. The rats were placed on a glass platform and allowed to habituate to the testing chambers for a minimum of 15 minutes prior to each testing session. The infrared thermal stimulus, delivered by means of a Thermal Plantar Test Instrument (Stoelting) set with a cutoff time of 15 seconds, was applied to the plantar surface of the paw of the operated limb. Thermal withdrawal latency was defined as the time (seconds) at the first pain behavioral response, and expressed as a percentage of the baseline to minimize the pooled standard deviation and, therefore, the sensitivity to treatment effects (i.e., differences between treatment groups).
statistical analysis
The power to detect effects on thermal withdrawal latency has been found to be maximized by expressing thermal withdrawal latency as a percentage of baseline. Using assumptions based on extensive historical data from SRI International (e.g., with latency expressed as a percentage of baseline, the pooled standard deviation is 10%), 8 animals per group provide greater than 80% power to reject the null hypothesis if there is a greater than 15% reduction in thermal withdrawal latency following treatment with any dose of rhBMP-2 (a = 0.05, 1-tailed). Powering of the study with a 1-tailed test is justified because the a priori research hypothesis was unidirectional (i.e., rhBMP-2 increases thermal hyperalgesia, or reduces thermal withdrawal latency); 2-tailed post hoc analyses were of an exploratory nature, as is typical of nonclinical research.
Thermal withdrawal latency data were analyzed by repeated-measures ANOVA applied to the entire data set (all 14 groups). Dunnett's multiple comparison tests were then used to compare each group to the saline-alone group for the respective cohort. Since there was significant interaction between time and treatment, factors were separated and further analyzed by 1-way ANOVA at each time point. Sidak's multiple comparison test was then applied to assess effects of sponge position (WRP vs ADJ) and rhBMP-2 dose. In all cases, a was set at 0.05.
Perfusion Fixation and tissue Collection
Twelve rats from each group were used for histological assessment of the nerve. Three animals from each group that did not undergo thermal testing were sacrificed on Days 3, 7, and 14 postoperatively. Following the completion of the behavioral testing on Day 28, 3 of the 8 rats from each group that underwent thermal testing were randomly selected and sacrificed by perfusion for tissue collection.
Whole-body perfusion was performed by placing the rats under deep isoflurane anesthesia followed by cannulation of the left heart ventricle for transcardial perfusion using a single-channel variable-flow mini-pump (VWR International). Each animal was perfused with 200 ml of cold 0.9% NaCl saline at a steady flow of approximately 20 ml/minute, followed by 200 ml of 4% paraformaldehyde (EM grade, Electron Microscopy Sciences).
After perfusion, the treated leg was collected from each animal, a small incision was made to expose the implant site, and the leg was immersed in Karnovsky's fixative (reagent grade, Electron Microscopy Sciences). The fixed tissue was refrigerated at 4°C.
histology
Tissue processing and histopathological evaluation was performed at Medtronic Physiological Research Laboratories. The collected sciatic nerves were trimmed transversely at the treated site and proximal and distal to the treated site. Longitudinal nerve segments that included the nerve interface with proximal and distal border of the implant were also trimmed ( Fig. 1) to facilitate in determining the mechanism of nerve damage and enhancing the sensitivity of finding nerve lesions.
One nerve cross-section was post-fixed in 2% osmium tetroxide and embedded in paraffin with the longitudinal sections. Paraffin-embedded tissues were cut with a microtome at 5 μm thick and stained with hematoxylin and eosin (H & E). Nerve transverse sections were post-fixed in 1% osmium tetroxide, embedded in epoxy resin and sectioned with an ultramicrotome at 1-μm thickness and stained with toluidine blue.
Microscopic evaluation was done via bright-field microscopy by a board-certified veterinary pathologist. All nerves were examined and assessed (Table 2) for histopathological changes indicative of nerve lesions, including inflammatory cell infiltration.
results

Clinical evaluations
All animals survived the entire length of the study. The animals in the Sham cohort, regardless of treatment group, displayed normal behavior. The animals in the CCI cohort, regardless of treatment group, developed postural abnormalities consistent with pain behaviors. All animals continued to groom themselves normally. 
behavioral testing
All behavioral test data are presented as a percentage of the baseline value recorded 2 days prior to surgery. The data were analyzed by repeated-measures ANOVA. Both time (F = 22.91, p < 0.001) and treatment (F = 37.64, p < 0.0001) main effects were significant. The interaction between main effects was also significant (F = 3.26, p < 0.0001). CCI produced a significant pain behavioral response in all treatment groups at all time points when compared with responses in the Sham saline group (p < 0.0001) (Fig. 2) .
Largely, animals in the Sham cohort had similar results regardless of treatment. On Day 14, rats that had the saline/ ACS implanted adjacent to the nerve were noted to have decreased thermal latency when compared with those receiving saline alone (p < 0.01). The animals that had 0.1 mg/ml rhBMP-2/ACS wrapped around the nerve showed a significant reduction in thermal latency on Day 28 when compared with those that received saline alone (p < 0.01). Compared with animals receiving saline alone, those that received 1.0 mg/ml rhBMP-2/ACS implanted adjacent to the nerve showed a significant reduction on Days 21 (p < 0.05) and 28 (p < 0.01).
An increased sensitivity to the thermal stimulus, thermal hyperalgesia, after CCI was observed for the salineonly treatment group on all days of testing. ACS (saline/ ACS WRP or ADJ) implanted in animals with CCI did not alter the pain behavioral response when compared with CCI with saline alone. Similarly, 0.1 mg/ml rhBMP-2/ ACS wrapped around the nerve had no effect on CCIinduced hyperalgesia. The group treated with 0.1 mg/ml rhBMP-2/ACS implanted adjacent to the nerve showed increased thermal latencies on Day 7 (p < 0.001). The group treated with 1.0 mg/ml rhBMP-2/ACS wrapped around the nerve showed increased thermal latencies on test Days 7 (p < 0.0001) and 14 (p < 0.05) relative to the group that received only saline, and animals with this treatment implanted adjacent to the nerve showed increased thermal latencies on Day 7 (p < 0.0001).
Post hoc analysis indicated no differences at any time point when comparing implanting the ACS wrapped around the sciatic nerve versus adjacent to the sciatic nerve. The only difference between the two rhBMP-2 concentrations compared against each other was in the CCI cohort on Day 7 with the 1.0 mg/ml rhBMP-2/ACS WRP group showing a significantly greater increase in thermal latency than the 0.1 mg/ml rhBMP-2/ACS ADJ group (13.9% reduction from baseline vs 30.3% reduction from baseline, respectively, p < 0.05).
histopathology
All the animals in all groups displayed minimal to mild edema, an expected result of the surgical manipulation. The presence of edema was most frequent at Days 3 and 7. Across all time points, the most notable histological changes to the sciatic nerves at the implant site were inflammatory cell infiltration, nerve fiber degeneration or loss, and occasional bone formation (Tables 3 and 4) .
In each group treated with ACS or sutures, the expected foreign-body response including inflammatory cell infiltration generally affected the connective tissue Mild changes: ~5% to 15% of the tissue affected; changes focal or multifocal but more pronounced than in minimal severity 3
Moderate changes: ~15% to 50% of the tissue affected; changes focal or multifocal but more pronounced than in mild severity 4
Marked changes: more than 50% of the nerve diameter affected surrounding the nerve, occasionally extending into the epineurium, and tended to be more severe through Day 7. Endoneurium inflammation was associated with traumainduced nerve lesions and was more severe and frequent in the CCI cohort, where nearly all the nerves had moderate to marked nerve damage induced by the sutures (Fig. 3) . The sutures were also associated with low numbers of neutrophils and multinucleated giant cells, whereas the ACS and surrounding host tissue generally had an infiltration of macrophages and neutrophils with occasional eosinophils and lymphocytes.
Histologically, the effect of rhBMP-2 on nerve inflammation was unclear in this study, as the inflammatory cell infiltration was generally similar in nerves treated with rhBMP-2/ACS to what was seen in nerves treated with saline/ACS. Rats treated with rhBMP-2/ACS without CCI generally had no or only mild inflammatory cell infiltration, and the inflammatory cell infiltration that was present was attributed to the ACS.
A subtle (minimal to mild) endoneurial infiltration of inflammatory cells was observed in all treatment groups in the Sham cohort. Moderate infiltration was observed in 2 rats treated with saline/ACS. Two rats treated with rhBMP-2/ACS demonstrated moderate to marked endoneurial or epineurial infiltration; however, prominent evidence of traumatic injury to the nerve was noted in these animals. Additionally, 15 of the 24 Sham cohort nerves treated with 1.0 mg/ml rhBMP-2/ACS had no evidence of endoneurium inflammatory cell infiltration.
Nerve damage was observed in all groups, although not all animals were affected. The lesions appeared to be induced by the trauma of the surgical placement of ACS and/or sutures, which also caused nerve atrophy (degeneration). In the Sham cohort, the rats treated with only saline generally had normal sciatic nerves, with only 1 rat having a "minimal" degree of axonal degeneration. Nerves treated with saline/ACS or with rhBMP-2/ACS, however, displayed characteristics of axonal degeneration and nerve atrophy. In nerves with CCI, axonal degeneration was generally severe, affecting most or all visible axons across the width of the nerve distal to proximal stump, and present in most nerves. The histological features were consistent with Wallerian-type degeneration and were generally characterized by a segmental, localized injury at the implant site (Fig. 3D) .
Osseous tissue was detected in all the groups treated with rhBMP-2. In some animals, nascent osseous tissue was identified as early as Day 7, but more often it was identified at Days 14 and 28. The bone generally formed outside the nerve. Osseous tissue formation in the nerve was found in 2 rats-in the epineurium of a Sham cohort rat treated with 0.1 mg/ml rhBMP2/ACS wrapped around the nerve (Fig. 3E and F) and in 1 nerve with CCI that was treated with 1.0 mg/ml rhBMP2/ACS wrapped around the nerve. In the latter nerve, ACS was found together with the new bone in the nerve, indicating that the rhBMP-2-loaded ACS was carried into the nerve, presumably by the CCI suture cutting into the nerve, where bone formed. Formation of bone in the soft tissues around the nerve was observed on gross examination at the latter time points but not evaluated further in order to avoid excessive nerve manipulation that could lead to histological artifacts.
Discussion
This study was conducted to test the hypothesis that rhBMP-2 applied to the sciatic nerve, either alone or in combination with CCI, induces neuropathic pain as assessed by thermal hyperalgesia. The CCI model was selected after the careful consideration of a couple of factors. Primarily, inflammatory pain models rely upon injecting irritants into the skin, paw, muscle, joint, or visceral organs. 7 The need to surgically implant the study articles introduces an uncharacterized variable that can be avoided by using alternative pain models. Secondly, inflammatory pain models generally have a short duration; 4, 22 whereas, in this study, we needed to have the pain state last throughout the bone-forming process triggered by rhBMP-2. The CCI model is a surgical model using loosely tied chromic gut sutures to trigger a macrophage-driven immunoinflammatory response that lasts about 60 days.
2,3 Another potential objection to the CCI model is the target of injury, the sciatic nerve, which contains postganglionic axons. With the exception of the lumbar nerve injury model reported by Hashizume et al., 10 in which pain-associated behaviors were largely resolved within 21 days, pain models impacting dorsal root ganglion cells all involve a tight ligation of or a complete transection of the nerve involved.
5 While the CCI model eliminates the specific assessment of the effect of test article(s) on sensory nerve cell bodies, the peripheral and central segments of sensory axons function as a single unit, with action potentials propagated without interruption as they pass by the soma (pseudounipolar axon).
13 Considering the limits imposed by using any of the alternative animal models used to assess pain, the CCI model was the only option available to directly assess changes in pain behaviors stimulated by rhBMP-2/ACS.
In the CCI model, pain behaviors can be assessed by thermal withdrawal latency (thermal hyperalgesia) or by von Frey assessment of mechanical withdrawal threshold (mechanical allodynia). A decision was made not to perform von Frey testing in this study after wide variations in the data were observed in preliminary studies. An inherent challenge with this model, as in all animal pain models, is that there are limits to the validity of extrapolating from induced animal pain behavioral responses to spontaneous human pain.
This study was divided into 2 cohorts. The Sham cohort was included in order to assess whether rhBMP-2/ ACS caused pain in a similar manner to the inflammationinducing ligatures used in the CCI model of neuropathic pain. Based on the results from this cohort, it appears that none of the components evaluated caused pain. The use of saline applied to the ACS, a component that elicits an inflammatory reaction and is resorbed by the host, did not elicit thermal hyperalgesia when compared with the use of saline alone. The position of the ACS, wrapped around the nerve or adjacent to the nerve, generally had no effect on pain behaviors. Glutamate, a known excitatory neurotransmitter, 9,20 is a constituent of the buffer present in the rhBMP-2 solution (2.5% glycine, 25.3 mM L-glutamic acid, 1.875 mM NaCl, 0.5% d-sucrose, 0.01% polysorbate 80; pH 4.5). This was considered as a potential trigger of the rhBMP-2-related radiculitis; however, in this model, the pain response to the buffer alone was comparable to the response to saline alone (data not shown). The CCI cohort was included to determine whether the rhBMP-2/ACS could amplify the pain caused by the sutures. Although the addition of the sutures produced statistically significant pain in all groups at all time points as determined by comparison with responses in the saline group of the Sham cohort, none of the components amplified the pain caused by the sutures used to generate the CCI.
A few in vitro studies have shown that rhBMP-2 has a neuroprotective effect. 6, 12, 15 At the earliest time points of the current in vivo study, results from the groups treated with rhBMP-2 in the CCI cohort appear to demonstrate a similar effect as evidenced by a transient reduction in thermal hyperalgesia. This effect diminishes over time, which could be related to the reduction of rhBMP-2 at the implant site over approximately 14 days. 18 By Day 28, rhBMP-2 induced a significant, dose-independent pain effect compared with saline in the Sham cohort; whereas the responses in the rhBMP-2 groups were not significantly different from those in the saline-treated group in the CCI cohort. Based on the trend of the rhBMP-2 behavioral results from both cohorts and the temporal pattern of bone formation observed on histological analysis, we propose that the pain observed in the rats is due to mechanical irritation by the newly induced bone rather than chemical irritation by rhBMP-2/ACS.
Histologically, Wallerian-type nerve damage affecting some axons within the nerve was observed following treatment with saline/ACS and following treatment with rhBMP-2/ACS. This is in contrast to the near-complete destruction of the nerve by CCI, distal to an intact proximal stump.
24 Treatment with rhBMP-2 was not associated with an increase of these histological changes. These findings are in contrast with the results of a study by Margolis et al. 17 who, with a similar animal model, found that rhBMP-2/ACS treatment was associated with axonal loss and the solidification of the myelin sheath. Margolis et al. did not have an ACS-alone group, a limitation they noted. Thus, it is possible that the observed changes to the nerve could have been due to mechanical irritation in response to the ACS rather than rhBMP-2. In the CCI model used in the current study, the sutures frequently caused prominent nerve trauma that was associated with inflammatory cell infiltration, which caused severe degeneration in most animals. The severity and incidence of nerve fiber degeneration was notably lower in groups without CCI, but was still present, particularly in the groups with ACS implants. The histological findings indicated that most of the animals used in this study had nerve damage caused by the surgical manipulation of the nerve that was required for ACS and/or suture placement.
Prior to surgery, the nerves in the present study were naïve. The treatments were administered concurrently with the nerve injury. Clinically, a patient undergoes fusion surgery after suffering for some period of time. It is unclear if rhBMP-2 would have the same short-term painreducing effect if the rats had been exposed to the CCI for a period of time prior to implanting rhBMP-2/ACS. Furthermore, as opposed to bone-healing models, there is no exposed bleeding bone (i.e., damaged bone) in this model. Damaged bone is necessary for the release of osteoclasts, osteoblasts, and the other inflammatory components that are required for bone healing. The presence of bleeding bone may produce different results in this model of neuropathic pain.
Conclusions
The results of this study do not support the hypothesis of pain caused by rhBMP-2 independent of bone formation. At the earliest time points, rhBMP-2 appeared to have a neuroprotective effect as evidenced by decreased pain exhibited by the rhBMP-2-treated animals in the CCI cohort. In the Sham cohort, there was a non-dose-related induction of pain at later time points, presumably due to new bone formation mechanically irritating the nerve. Histologically, the observed nerve lesions appeared to be caused by mechanical trauma associated with surgical manipulation of the nerve during placement of the ACS and/ or CCI sutures, with more severe lesions in animals treated with CCI.
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